Trends in patient and technique survival in peritoneal dialysis and strategies: How are we doing and how can we do better?

Advances in Renal Replacement Therapy

Volumn 7, Issue 4, 2000, Pages 324-337

  Blake, P G ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Cardiovascular disease; Mortality rates; Peritoneal dialysis; Technique failure

Indexed keywords

CANADA; CARDIOVASCULAR DISEASE; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; HEMODIALYSIS; HUMAN; HYPERHOMOCYSTEINEMIA; LONG TERM CARE; MALNUTRITION; MORTALITY; NORTH AMERICA; PATIENT CARE; PERITONEAL DIALYSIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SURVIVAL RATE; UNITED STATES;

EID: 0033770296     PISSN: 10734449     EISSN: None     Source Type: Journal    
DOI: 10.1053/jarr.2000.16531     Document Type: Article

References (55)

1. Changes in demographics and prescription of PD during the last decade
2. Five-year survival for end-stage renal diseases patients in the United States, Europe and Japan 1982- 1987
3. Cardiovascular disease in peritoneal dialysis patients: The size of the problem
4. Survival advantage in Asian-American end-stage renal disease patients
5. Changes in the dose of peritoneal dialysis: Have these independently affected outcomes?
6. A critical examination of trends in outcomes over the last decade
7. Trends in mortality on peritoneal dialysis: Canada 1981- 1997
8. Improved survival in renal replacement therapy in Europe between 1975 and 1992. An ERA-EDTA study
9. A comparison of mortalities between patients treated with hemodialysis and peritoneal dialysis
10. Comparing mortality rates on CAPD/CCPD and hemodialysis. The Canadian Experience: Fact or Fiction?
11. 1983-1992: Report on regular dialysis and transplantation in Lombardy
12. A multicenter, selection adjusted comparison of patient and technique survivals on CAPD and hemodialysis: A multicenter study
13. Factors affecting international utilization of peritoneal dialysis: Implications for increasing utilization in the United States
14. Mortality risks of peritoneal dialysis and hemodialysis
15. An evaluation of an integrative care approach for endstage renal disease patients
16. Trends in clinical indicators of care for adult peritoneal dialysis patients in the United States from 1995 to 1997. ESRD Core Indicators Workgroup
17. Changes in CAPD prescription in Canada 1996-99
18. Impact of hypertension on cardiomyopathy, morbidity and mortality in end-stage renal disease
19. Low diastolic blood pressure, hypoalbuminemia, and risk of death in a cohort of chronic hemodialysis patients
20. Conceptual model for a core pathobiology of uremia with special reference to anemia, malnourishment and mortality among dialysis patients
21. Risk factors for 5-year mortality in older adults: The Cardiovascular heath study
22. Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency
23. Congestive heart failure in dialysis patients: Prevalence, incidence, risk factors and prognosis
24. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin
25. Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease
26. Plasma total homocysteine is influenced by nutritional status in hemodialysis patients
27. Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients: A prospective study
28. Lp(a) lipoprotein in cardiovascular disease
29. Lipoprotein (a) is an independent risk factor for cardiovascular disease in hemodialysis patients
30. Prevalence of hyperlipidemia in a cohort of CAPD patients
31. Lipid-lowering therapy in patients with renal disease
32. The use of glucose polymer (icodextrin) in peritoneal dialysis: An overview
33. Modeling success or failure of dialysis therapy: The National Cooperative Dialysis Study (NCDS)
34. Malnutrition, cardiac disease and mortality: An integrated point of view
35. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure
36. Serum albumin in patients on CAPD
37. Acute phase determinants and peritoneal dialysate albumin losses are main determinants of serum albumin in PD patients
38. Inflammation, aspirin and the risk of cardiovascular disease in apparently healthy men
39. Controlling the epidemic of cardiovascular disease: What do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease
40. Trends in CAPD technique failure rates: Canada 1981-1997
41. Peritonitis as a complication of peritoneal dialysis
42. Prospective controlled trial of a Y-connector and disinfectant to prevent peritonitis in CAPD
43. Prevention of peritonitis with disconnect systems in CAPD: A randomized controlled trial. The Mexican Nephrology Collaborative Study Group
44. Nasal mupirocin prevents Staphylococcus aureus exit site infection during peritoneal dialysis
45. Clinical practice guidelines for peritoneal dialysis adequacy
46. Guidelines for adequacy and nutrition in peritoneal dialysis
47. Issues affecting the longevity of the continuous peritoneal dialysis therapy
48. Increased peritoneal membrane transport is associated with decreased patient and technique survival for continuous peritoneal dialysis patients
49. Peritoneal dialysis-related peritonitis treatment recommendations, 1996 update